New Zealand markets closed

Bio-Rad Laboratories, Inc. (BIO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
346.80-2.76 (-0.79%)
As of 02:26PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 9.88B
Enterprise value 9.68B
Trailing P/E N/A
Forward P/E 31.35
PEG ratio (5-yr expected) 1.19
Price/sales (ttm)3.82
Price/book (mrq)1.14
Enterprise value/revenue 3.62
Enterprise value/EBITDA -14.78

Trading information

Stock price history

Beta (5Y monthly) 0.87
52-week change 3-25.91%
S&P500 52-week change 329.57%
52-week high 3494.05
52-week low 3261.59
50-day moving average 3330.37
200-day moving average 3344.81

Share statistics

Avg vol (3-month) 3200.66k
Avg vol (10-day) 3177.21k
Shares outstanding 523.42M
Implied shares outstanding 628.54M
Float 819.95M
% held by insiders 115.23%
% held by institutions 181.71%
Shares short (15 Mar 2024) 4579.33k
Short ratio (15 Mar 2024) 42.42
Short % of float (15 Mar 2024) 42.87%
Short % of shares outstanding (15 Mar 2024) 42.03%
Shares short (prior month 15 Feb 2024) 4587.1k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 308 Mar 2002

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -23.86%
Operating margin (ttm)14.24%

Management effectiveness

Return on assets (ttm)1.77%
Return on equity (ttm)-6.94%

Income statement

Revenue (ttm)2.67B
Revenue per share (ttm)91.45
Quarterly revenue growth (yoy)-6.70%
Gross profit (ttm)N/A
EBITDA 511.6M
Net income avi to common (ttm)-637.32M
Diluted EPS (ttm)-21.81
Quarterly earnings growth (yoy)-57.80%

Balance sheet

Total cash (mrq)1.61B
Total cash per share (mrq)56.35
Total debt (mrq)1.41B
Total debt/equity (mrq)16.08%
Current ratio (mrq)5.83
Book value per share (mrq)306.51

Cash flow statement

Operating cash flow (ttm)374.9M
Levered free cash flow (ttm)170.82M